FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma

On October 23, the FDA approved belantamab mafodotin-blmf, a B-cell maturation antigen-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

For more information, read the FDA announcement and the GlaxoSmithKline press release.

Posted on 10/27/2025